The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates

Nature Reviews Drug Discovery

Volumn 6, Issue 8, 2007, Pages 636-649

  Kramer, Jeffrey A ^a   Sagartz, John E ^b   Morris, Dale L ^c  

^a LEXICON PHARMACEUTICALS INC   (United States)

^b Seventh Wave Laboratories   (United States)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE A2A RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; BENAZEPRIL; CAPTOPRIL; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOPAMINE 3 RECEPTOR BLOCKING AGENT; FENFLURAMINE; IBUPROFEN; INDOMETACIN; MEFENAMIC ACID; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; NAPROXEN; NEW DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; NORFENFLURAMINE; PARACETAMOL; PERINDOPRIL; PHOSPHODIESTERASE IV INHIBITOR; PIROXICAM; QUINAPRIL; RALOXIFENE; RAMIPRIL; ROFECOXIB; SODIUM CHANNEL BLOCKING AGENT; UNINDEXED DRUG; VALDECOXIB;

BLEEDING; BLEEDING TIME; DIGESTIVE SYSTEM ULCER; DRUG CHOICE; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG MARKETING; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; GENOTOXICITY; HIGH THROUGHPUT SCREENING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PATHOLOGY; PEPTIC ULCER; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REPEATED DRUG DOSE; REVIEW; SIDE EFFECT; TOXICITY TESTING; TOXICOLOGY; VALVULAR HEART DISEASE;

ANIMALS; CLINICAL TRIALS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; MODELS, BIOLOGICAL; PHARMACOGENETICS; TECHNOLOGY, PHARMACEUTICAL; TOXICITY TESTS;

EID: 34547656228     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2378     Document Type: Review

References (164)

1. Reichert, J. M. Trends in development and approval times for new therapeutics in the United States. Nature Rev. Drug Discov. 2 695-702 (2003).
2. Pharmaceutical Research and Manufacturers of America (PhRMA). Pharmaceutical Industry Profile 2005. (PhRMA, Washington DC, 2005).
3. Booth, B. & Zemmel, R. Prospects for productivity. Nature Rev. Drug Discov. 3, 451-456 (2004).
4. Centre for Medicines Research (CMR) International. 2005 Global R&D Performance Metrics Programme. Industry Success Rates Report. (CMR International, Epsom, 2005).
5. DiMasi, J. A., Hansen, R. W. & Grabowski, H. G. The price of innovation: new estimates of drug development costs. J. Health Econ. 22, 151-185 (2003).
6. Prentis, R. A., Lis, Y. & Walker, S. R. Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985). Br. J. Clin. Pharmacol. 25, 387-396 (1988).
7. Kola, I. & Landis, J. Can the pharmaceutical industry reduce attrition rates? Nature Rev. Drug Discov. 3, 711-715 (2004).
8. Feng, W. Y. Mass spectrometry in drug discovery: A current review. Curr. Drug Discov. Technol. 1, 295-312 (2004).
9. Alden, C. L. et al. The pathologist and toxicologist in pharmaceutical product discovery. Toxicol. Pathol. 27, 104-106 (1999).
10. Olson, H. et al. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul. Toxicol. Pharmacol. 32, 56-67 (2000).
11. Greaves, P., Williams, A. & Eve, M. First dose of potential new medicines to humans: How animals help. Nature Rev. Drug Discov. 3, 226-236 (2004).
12. Booth, B. L., Lennon, D. J. & McCafferty, E. J. Improving the pharma research pipeline. McKinsey O. 4, 9-11 (2004).
13. Boston Consulting Group. in Parexel's Pharmaceutical R&D Statistical Sourcebook 2002/2003. (ed. Mathieu, M. P.) (Parexel Int Corp., Waltham, Massacheusetts, 2002).
14. US Food and Drug Administration (FDA). Innovation or Stagnation? Challenge and opportunity on the critical path to new medicinal products. FDA web site [online],
15. Serabian, M. A. & Pilaro, A. M. Safety assessment of biotechnology-derived pharmaceuticals: ICH and beyond. Toxicol. Pathol. 27, 27-31 (1999).
16. Medjitna, T. D., Stadler, C., Bruckner, L., Griot, C. & Ottiger, H. P. DNA vaccines: Safety aspect assessment and regulation. Dev. Biol. 126, 261-270 (2006).
17. Ames, B. N., McCann, J. & Yamasaki, E. Methods for detecting carcinogens and mutagens with the Salmonella/mammalian-microsome mutagenicity test. Mutat. Res. 31, 347-364 (1975).
18. + reversion in Escherichia coli, Mutat. Res. 38, 3-32 (1976).
19. Maron, D. M. & Ames B. Revised methods for the Salmonella mutagenicity test Mutat. Res. 113, 173-215 (1983).
20. Galloway, S. M. et al. Report from working group on in vitro tests for chromosomal aberrations. Mutat. Res. 312, 241-261 (1994).
21. Tennant R. W. et al. Prediction of chemical carcinogenicity in rodents from in vitro genetic toxicity assays. Science 236, 933-941 (1987).
22. Kirkland, D., Aardema, M., Henderson, L. & Muller, L. Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens I. Sensitivity, specificity and relative predictivity. Mutat. Res. 584, 1-256 (2005).
23. Cote, C., Blaise, C., Delisle, C. E., Meighen, E. A. & Hansen, P. D. A miniaturized Ames mutagenicity assay employing bioluminescent strains of Salmonella typhimurium. Mutat Res. 345, 137-146 (1995).
24. Green, M. H., Muriel, W. J. & Bridges, B. A. Use of a simplified fluctuation test to detect low levels of mutagens. Mutat. Res. 38, 33-42 (1976).
25. Van Gompel, J. et al. An assessment of the utility of the yeast GreenScreen assay in pharmaceutical screening. Mutagenesis 20 449-454 (2005).
26. Quillardet, P. & Hofnung, M. The SOS chromotest: A review. Mutat. Res. 297, 235-279 (1993).
27. Verschaeve, L. et al. VITOTOX bacterial genotoxicity and toxicity test for the rapid screening of chemicals. Environ. Mol. Mutagen. 33, 240-248 (1999).
28. Romagna, F. & Staniforth, C. D. The automated bone marrow micronucleus test. Mutat. Res. 213, 91-104 (1989).
29. Dertinger, S. D., Torous, D. K. & Tometsko, K. R. Flow cytometric analysis of micronucleated reticulocytes in mouse bone marrow. Mutat Res. 390, 257-262 (1997).
30. Styles, J. A., Clark, H., Festing, M. F. & Rew, D. A. Automation of mouse micronucleus genotoxicity assay by laser scanning cytometry. Cytometry 44, 153-155 (2001).
31. Kirpnick, Z. et al. Yeast DEL assay detects clastogens. Mutat. Res. 582, 116-34 (2005).
32. Shuga, J., Zhang, J., Samson, L. D., Ladish, H. F. & Griffith, L. G. In vitro erythropoiesis from bone marrow-derived progenitors provides a physiological assay for toxic and mutagenic compounds. Proc. Natl. Acad. Sci. USA 104, 8737-8742 (2007).
33. 2c receptor agonists by the incorporation of a gem-dimethyl group: SAR using the Ames test and a DNA unwinding assay. Mutagenesis 13, 397-403 (1998).
34. Hu, T. et al. Identification of a gene expression profile that discriminates indirect-acting genotoxins from direct-acting genotaxins. Mutat. Res. 549, 5-27 (2004).
35. Newton, R. K., Aardema, M. & Aubrecht, J. The utility of DNA microarrays for characterizing genotoxicity. Environ. Health Perspect. 112 420-422 (2004).
36. Yap, Y. G. & Camm, A. J. Arrhythmogenic mechanisms of non-sedating antihistamines. Clin. Exp. Allergy 29 (Suppl. 3), 174-181 (1999).
37. Hoffmann, P. & Warner, B. Are hERG channel inhibition and OT interval prolongation all there is in drug-induced torsadogenesis? A review of emerging trends. J. Pharmacol. Toxicol. Methods 53, 87-105 (2006).
38. De Ponti, F., Poluzzi, & Montanato, N. OT-interval prolongation by non-cardiac drugs: Lessons to be learned from recent experience. Eur. J. Clin. Pharmacol. 56, 1-18 (2000).
39. Murphy, S. M. et al. Evaluation of functional and binding assays in cells expressing either recombinant or endogenous hERG channel. J. Pharmacol. Toxicol. Methods 52, 42-55 (2006).
40. Chaudhary, K. W. et al. Evaluation of the rubidium efflux assay for preclinical identification of HERG blockade. Assay Drug Dev. Technol. 4, 73-82 (2006).
41. Matasi. J. J. et al. 2-(2-Furanyl)-7-phenyl[1,2,4]triazolo [1,5-c]pyrimidin-5-amine analogs as adenosine A2A antagonists: The successful reduction of hERG activity. Part 2. Bioorg. Med. Chem. Lett. 15, 3675-3678 (2005).
42. Friesen, R. W. et al. Optimization of a tertiary alcohol series of phosphodiesterase-4 (PDE4) inhibitors: Structure - activity relationship related to PDE4 inhibition and human ether-a-go-go related gene potassium channel binding affinity. J. Med. Chem. 46, 2413-2426 (2003).
43. Wienkers, L. C. & Heath, T. G. Predicting in vivo drug interactions from in vitro drug discovery data. Nature Rev. Drug Discov. 4, 825-833 (2005).
44. Hollo, Z., Homolya, L., Davis, C. W. & Sarkadi, B. Calcein accumulation as a fluorometric functional assay of the multidrug transporter. Biochim. Biophys. Acta 1191, 384-388 (1994).
45. Ashwell, M. A. et al. The design, preparation and SAR of novel small molecule sodium (Na(+)) channel blockers. Bioorg. Med. Chem. Lett. 14, 2025-2030 (2004).
46. 3 receptor antagonist. J. Med. Chem. 46, 4952-4964 (2003).
47. Revesz, L. et al. SAR of 4-hydroxypiperidine and hydroxyalkyl substituted heterocycles as novel p38 map kinase inhibitors. Bioorg. Med. Chem. Lett. 10, 1261-1264 (2000).
48. Wang, S. et al. Design and synthesis of new templates derived from pyrrolopyrimidine as selective multidrug-resistance-associated protein inhibitors in multidrug resistance. J. Med. Chem. 47, 1389-1350 (2004).
49. Baillie, T. A. et al. Drug metabolites in safety testing. Toxicol. Appl. Pharmacol. 182, 188-196 (2002).
50. Vignati, L. et al. An in vitro approach to detect metabolite toxicity due to CYP3A4-dependent bioactivation of xenobiotics. Toxicology 216, 154-167 (2005).
51. Walgren, J. L., Mitchell, M. D. & Thompson, D. C. Role of metabolism in-drug-induced idiosyncratic hepatotoxicity. Crit. Rev. Toxicol. 35, 325-361 (2005).
52. Park, K., Williams, D. P., Naisbitt, D. J., Kitteringham, N. R. & Pirmohamed, M. Investigation of toxic metabolites during drug development. Toxicol. Appl. Pharmacol. 207 (Suppl. 2), 425-434 (2005).
53. Evans, D. C., Watt, A. P., Nicoll-Griffith, D. A. & Baillie, T. A. Drug-protein adducts: An industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem. Res. Toxicol. 17, 3-16 (2004).
54. Chen, O. et al.. Cytochrome P450 3A4-mediated bioactivation of raloxifene: Irreversible enzyme inhibition and thiol adduct formation. Chem. Res. Toxicol. 15, 907-914 (2002).
55. Baillie, T. A. Future of toxicology-metabolic activation and drug design: Challenges and opportunities in chemical toxicology. Chem. Res. Toxicol. 19, 889-893 (2006).
56. Mesfin, G. M. et al. Pathogenesis of cardiovascular alterations in dogs treated with minoxidil. Toxicol. Pathol. 17, 164-181 (1989).
57. Mesfin, G. M., Robinson, F. G., Higgins. M. J. Zhong, W. Z. & DuCharme, D. W. The pharmacologic basis of the cardiovascular toxicity of minoxidil in the dog. Toxicol. Pathol. 23, 498-506 (1995).
58. Mesfin, G. M., Higgins, M. J., Robinson, F. G. & Zhong. W. Z. Relationship between serum concentrations, hemodynamic effects, and cardiovascular lesions in dogs treated with minoxidil. Toxicol. Appl. Pharmacol. 140, 337-344 (1996).
59. Kerns, W. et al. (Expert Working Group on Drug-Induced Vascular Injury). Drug-induced vascular injury-a quest for biomarkers. Toxicol. Appl. Pharmacol. 203, 62-87 (2005).
60. Gonzalez. F. J. Recent update on the PPARα-null mouse. Biochimie 79, 139-144 (1997).
61. Park. B, K. Pirmohamed, M. & Kitteringham, N. R. Role of drug disposition in drug hypersensitivity: A chemical, molecular, and clinical perspective. Chem. Res. Toxicol. 11, 969-988 (1998).
62. Edwards, I. R. & Aronson, J. K. Adverse drug reactions: Definitions, diagnosis, and management. Lancet 356, 1255-1259 (2000).
63. Roth, R. A., Luyendyk, J. P., Maddox, J. F. & Ganey, P. E. Inflammation and drug idiosyncrasy - is there a connection? J. Pharmarcol. Exp. Ther. 307, 1-8 (2003).
64. Tafazoli, S., Spehar, D. D. & O'Brien, P. J. Oxidative stress mediated idiosyncratic drug toxicity. Drug Metab. Rev. 37, 311-325 (2005).
65. Waring, J. F. et al. Microarray analysis of lipopolysaccharide potentiation of trovafloxacin-induced liver injury in rats suggests a role for proinflammalory chemokines and neutrophils. J. Pharmacol. Exp. Ther. 316, 1080-1087 (2006).
66. Elcombe, C. R. et al. Prediction of rodent nongenotoxic carcinogenesis: Evaluation of biochemical and tissue changes in rodents following exposure to nine nongenotaxic NTP carcinogens. Environ. Health Perspect. 110, 363-375 (2002).
67. Kramer, J. A. et al. Acute molecular markers of rodent hepatic carcinogenesis identified by transcription profiling. Chem. Res. Toxicol. 17, 463-470 (2004).
68. Tabacova, S. Mode of action: Angiotensin-converting enzyme inhibition - developmental effects associated with exposure to ACE inhibitors. Crit. Rev. Toxicol. 35, 747-755 (2005).
69. Valdes, G., Marinovic, D., Falcon. C., Chuaqui. R. & Duarte, I. Placental alterations, intrauterine growth retardation and teratogenicity associated with enalapril use in pregnant rats. Biol. Neonate 61, 124-130 (1992).
70. Hilgers, K. F., Reddi, V., Krege, J. H., Smithies, O. & Gomez, R. A. Aberrant renal vascular morphology and renin expression in mutant mice lacking angiotensin-converting enzyme. Hypertension 29, 216-221 (1997).
71. Matsushima, N. et al. Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: A multiple-dose study in healthy humans. Platelets 17, 218-226 (2006).
72. Orford, J. L. et al. Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation. Am. Heart J. 147, 463-467 (2004).
73. Daykin, H. J., Sturgeon, S. A., Jones, C. & Wright, C. E. Arterial antithrombotic effects of aspirin, heparin. enoxaparin and clopidogrel alone, or in combination, in the rat. Thromb. Res. 118, 755-762 (2006).
74. Sugidachi. A., Asai, F., Ogawa, T., Inoue, T. & Koike, H. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties. Br. J. Pharmacol. 129, 1439-1446 (2000).
75. Elg, M., Gustafsson, D. & Carlsson S. Antithrombotic effects and bleeding time of thrombin inhibitors and warfarin in the rat. Thromb. Res. 94, 187-197 (1999).
76. Schumacher, W. A., Heran, C. L. & Steinbacher, T. E. Low-molecular-weight heparin (fragmin) and thrombin active-site inhibitor (argatroban) compared in experimental arterial and venous thrombosis and bleeding time. J. Cardiovasc. Pharmacol. 28, 19-25 (1996).
77. Connolly, H. M. et al. Valvular heart disease associated with fenfluramine-phentermine. N. Engl. J. Med. 337, 581-588 (1997).
78. 2C receptor agonists: Potential for the treatment of obesity. Mol. Interv. 5, 282-291 (2005).
79. Fitzgerald, L. W. et al. Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine. Mol. Pharmacol. 57, 75-81 (2000).
80. Rothman, R. B. et al. Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 102, 2836-2841 (2000).
81. 2C aganists in treating obesity. Expert Opin. Investig. Drugs. 15, 257-266 (2006).
82. Silverstein, F. E. et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid Arthritis: The CLASS study: a randomized controlled trial. Celecoxib Longterm Arthritis Safety Study. JAMA 284, 1247-1255 (2000).
83. Bombardier, C. et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N. Engl. J. Med. 343, 1520-1528 (2000).
84. Reasor, M. J. & Kacew. S. Drug-induced phospholipidosis: Are there functional consequences? Exp. Biol. Med. 226, 825-830 (2001).
85. Reasor, M. J., Hastings, K. L. & Ulrich, R. G. Drug-induced phospholipidosis: Issues and future directions. Expert Opin. Drug Saf. 5, 567-583 (2006).
86. Foroozesh, M. et al. Aryl acetylenes as mechanism-based inhibitors of cytochrome P450-dependent monooxygenase enzymes. Chem. Res. Toxicol. 10, 91-102 (1997).
87. Helvig, C. et al. Suicide inactivation of cytochrome P450 by midchain and terminal acetylenes. A mechanistic study of inactivation of a plant lauric add ω-hydroxylase. J. Biol. Chem. 272, 414-421 (1997).
88. Zhou, S. et al. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin. Pharmocokinet. 44, 279-304 (2005).
89. Wolfe, A., Shimer, G. H. Jr & Meehan, T. Polycyclic aromatic hydrocarbons physically intercalate into duplex regions of denatured DNA. Biochemistry 26, 6392-6396 (1987).
90. Topliss, J. G. Utilization of operational schemes for analog synthesis in drug design. J. Med. Chem. 15, 1006-1011 (1972).
91. Renkiewicz, R. et al. Broad-spectrum matrix-metalloproteinase inhibitor marimastat-induced musculoskeletal side effects in rats. Arthritis Rheum. 48, 1742-1749 (2003).
92. Kramer, J. A. et al. Transcription profiling distinguishes dose-dependent effects in the livers of rats treated with clofibrate. Toxicol. Pathol. 31, 417-431 (2003).
93. Elrick, M. M. et al. Differential display in rat livers treated for 13 weeks with phenobarbital implicates a role fior metabolic and oxidative stress in nongenotoxic carcinogenicity. Toxicol. Pathol. 33, 118-126 (2005).
94. Amin, R. P. et al. Identification of putative gene based markers of renal toxicity. Environ. Health Perspect. 112, 465-479 (2004).
95. Bendele, A. et al. Animal models of arthritis: Relevance to human disease. Toxicol. Pathol. 37, 134-142 (1999).
96. March, T H., Green, F. H., Hahn, F. F. & Nikula, K. J. Animal models of emphysema and their relevance to studies of particle-induced disease. Inhal. Toxicol. 12 (Suppl. 4). 155-187 (2000).
97. Nikula, K. J. & Green, F. H. Animal models of chronic bronchitis and their relevance to studies of particle-induced disease. Inhal. Toxicol. 12 (Suppl. 4), 123-153 (2000).
98. Heyen, J. R., et al. Structural, functional, and molecular characterization of the SHHF model of heart failure. Am. J. Physiol. Heart Circ. Physiol. 283, H1775-H1784 (2002).
99. March, T. H., Barr, E. B., Finch, G. L., Nikula, K. J. & Seagrave, J. C. Effects of concurrent ozone exposure on the pathogenesis of cigarette smoke-induced emphysema in B6C3F1 mice. Inhal. Toxicol. 14, 1187-1213 (2002).
100. Weinreb, D. B., Aguinaldo, J. G., Feig, J. E., Fishec E. A. & Fayad. Z. A. Non-invasive MRI of mouse models of atherosclerosis. NMR Biomed. 20, 256-264 (2007).
101. Joner. M. et al. Pioglitazone inhibits in-stent restenosis in atherosclerotic rabbits by targeting transforming growth factor-β and MCP-1. Arterioscler. Thromb. Vasc. Biol. 27, 182-189 (2007).
102. -/- mouse model of atherosclerosis. Life Sci. 78, 1983-1989 (2006).
103. Jaakkola, K. et al. In vivo detection of vascular adhesion protein-1 in experimental inflammation. Am. J. Pathol. 157, 463-471 (2000).
104. Hicks, S. M. et al. Immunohistochemical analysis of Clara cell secretary protein expression in a transgenic model of mouse lung carcinogenesis. Toxicology. 187, 217-228 (2003).
105. Blomme, E. A. et al. Selective cyclooxygenase-2 inhibition does not affect the healing of cutaneous full-thickness incisional wounds in SKH-1 mice. Br. J. Dermatol. 148, 211-223 (2003).
106. Blasi, E. R. et al. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int. 63, 1791-1800 (2003).
107. Khan, K. N. et al. Interspecies differences in renal localization of cyclooxygenase isoforms: Implications in nonsteroidal anti-inflammartory drug-related nephrotaxicity. Toxicol. Pathol. 26, 612-620 (1998).
108. Sellers, R. S., Senese, P. B. & Khan, K. N. Interspecies differences in the nephrotoxic response to cyclooxygenase inhibition. Drug. Chem. Toxicol. 27, 111-122 (2004).
109. Jones, M. B. et al. Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer. Proteomics 2, 76-84 (2002).
110. Koop, R. Combinartorial biomarkers: From early toxicology assays to patient population profiling. Drug Discov. Today. 10, 781-788 (2005).
111. Gundert-Remy, U. et al. Molecular approaches to the identification of biomarkers of exposure and effect - report of an expert meeting organized by COST Action B15. Toxicol. Lett. 156, 227-240 (2005).
112. Thukral, S. K. et al. Prediction of nephrotoxicant action and identification of candidate toxicity-related biomarkers. Toxicol. Pathol. 33, 343-355 (2005).
113. Petricoin, E. F. et al. Toxicoproteomics: Serum proteomic pattern diagnostics for early detection of drug induced cardiac toxicities and cardioprotection. Toxicol. Pathol. 32 (Suppl. 1), 122-130 (2004).
114. Searfoss, G. H. et al. Adipsin, a biomarker of gastrointestinal toxicity mediated by a functional γ-secretase inhibitor. J. Biol. Chem. 278, 46107-46116 (2003).
115. Moody, D. E., Reddy, J. K., Lake, B. G. Popp, J. A. & Reese, D. H. Peroxisome proliferation and nongenotoxic carcinogenesis: Commentary on a symposium. Fundam. Appl. Toxicol. 16, 233-248 (1991).
116. Tugwood, J. D. Aldridge, T. C., Lambe, K. G., Macdonald, N. & Woodyatt, N. J. Peroxisome proliferator-activated receptor-α and the pleiotropic responses to peroxisome proliferators. Arch. Toxicol. Suppl. 20 377-386 (1998).
117. Woodyatt, N. J., Lambe, K. G., Myers, K. A., Tugwood, J. D. & Roberts, R. A. The peroxisome proliferator (PP) response element upstream of the human acyl CoA oxidase gene is inactive among a sample human population: significance for species differences in response to PPs. Carcinogenesis 20, 369-372 (1999).
118. Cattley, R. C. et al. Do peroxisome proliferating compounds pose a hepato-carcinogenic hazard to humans? Regul. Toxicol. Pharmocol. 27, 47-60 (1998).
119. McClain, R. M., Posch, R. C., Bosakowski, T. & Armstrong, J. M. Studies on the mode of action for thyroid gland tumor promotion in rats by phenobarbital. Toxicol. Appl. Pharmacol. 94, 254-265 (1988).
120. McClain, R. M. Thyroid gland neoplasia: Non-genotoxic mechanisms. Toxicol, Lett. 64-65, 397-408 (1992).
121. Williams, E. D. Mechanisms and pathogenesis of thyroid cancer in animals and man. Mutat. Res. 333, 123-129 (1995).
122. Davila, J. C. et al. Use and application of stem cells in toxicology. Toxicol. Sci. 79, 214-223 (2004).
123. Gross. C. J. & Kramer, J. A. The role of investigative molecular toxicology in early stage drug development. Expert Opin. Drug Saf. 2, 147-159 (2003).
124. Walgren, J. L. & Thompson, D. C. Application of proteomic technologies in the drug development process. Toxicol. Lett. 149, 377-385 (2004).
125. Griffin, J. L. & Bollard, M. E. Metabonomics: Its potential as a tool in toxicology for safety assessment and data integration. Curr. Drug Metab. 5, 389-398 (2004).
126. Heijne, W. H., Kienhuis, A. S., van Ommen, B., Stierum, R. H. & Groten, J. P. Systems toxicology: Applications of toxicogenomics, transcriptomics, proteomics and metabolomics in toxicology. Expert Rev. Proteomics 2, 767-780 (2005).
127. Ulrich, R. & Friend, S. H. Toxicogenomics and drug discovery: Will new technologies help us produce better drugs? Nature Rev. Drug Discov. 1, 84-88 (2002).
128. Kramer, J. A. & Kolaja, K. L. Toxicogenomics: An opportunity to optimise drug development and safety evaluation. Expert Opin. Drug Saf. 1, 275-286 (2002).
129. Rodi, C. P. et al. Revolution through genomics in investigative and discovery toxicology. Toxicol. Pathol. 27, 107-10 (1999).
130. Gomez-Brouchet A. et al. Critical role for sphingosine kinase-1 in regulating survival of neuroblastoma cells exposed to amyloid β peptide. Mol. Pharmacol. 23 May 2007 (doi: 10.1124/mol. 106.033738).
131. Tateno, C. et al. Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am. J. Pathol. 165, 901-912 (2004).
132. +/- knockout mice: overview of available data. Toxicol. Pathol. 29 (Suppl. 1), 117-127 (2001).
133. Tennant, R. W., Stasiewicz, S., Eastin, W. C., Mennear, J. H. & Spalding, J. W. The Tg. AC (v-Ha-ras) transgenic mouse: Nature of the model. Toxicol. Pathol. 29 (Suppl. 1), 51-59 (2001).
134. +/- hemizygous knockout mouse: Overview of available data. Toxicol. Pathol. 29 (Suppl. 1), 30-50 (2001).
135. Bolon, B. Genetically engineered animals in drug discovery and development: A maturing resource for toxicologic research. Basic Clin. Pharmacol. Toxicol. 95, 154-161 (2004).
136. Vadolas, J. et al. Humanized β-thalassemia mouse model containing the common IVSI-110 splicing mutation. J. Biol. Chem. 281, 7399-7405 (2006).
137. McMillian, M. K. et al. Nile Red binding to HepG2 cells: An improved assay for in vitro studies of hepatosteatosis. In Vitr. Mol. Toxicol. 14, 177-190 (2001).
138. Gum, R. J. et al. Analysis of two matrix metalloproteinase inhibitors and their metabolites for induction of phospholipidosis in rat and human hepatocytes. Biochem. Pharmacol. 62, 1661-1673 (2001).
139. Morelli, J. K. et al. Validation of an in vitro screen for phospholipidosis using a high-content biology platform. Cell. Biol. Toxicol. 22, 15-27 (2006).
140. Portera-Cailliau, C., Sung, C. H., Nathans, J. & Adler, R. Apoptotic photoreceptor cell death in mouse models of retinitis pigmentosa. Proc. Natl Acad. Sci. US4 91, 974-978 (1994).
141. Fairbairn, D. W., Olive, P. L. & O'Neill, K. L. The comet assay: A comprehensive review. Mutat. Res. 339, 37-59 (1995).
142. Vermes, I., Haanen, C., Steffens-Nakken, H. & Reutelingsperger, C. A novel assay for apoptosis. Flow cytometric detection of phosphatisdylserine expression on early apoptotic cells using fluorescein labeled Annexin V. J. Immunol. Methods 184, 39-51 (1995).
143. Curtu, V., Min, S. R. & Zhang, G. Fluorometric and colorimetric detection of caspase activity associated with apoptosis. Anal. Biochem. 251, 98-102 (1997).
144. Hyslop, P. A. & Sklar, L. A. A quantitative fluorimetric assay for the determination of oxidant production by polymorphonuclear leukocytes: Its use in the simultaneous fluorimetric assay of cellular activation processes. Anal. Biochem. 141, 280-286 (1984).
145. Capaldi, R. A., Murray, J., Byrne, L., Janes, M. S. & Marusich, M. F. Immunological approaches to the characterization and diagnosis of mitochondrial disease. Mitochondrion 4, 417-426 (2004).
146. Letteron P., Sutton, A., Mansouri, A., Fromenty, B. & Pessayre, D. Inhibition of microsomal triglyceride transfer protein: Another mechanism for drug-induced steatosis in mice. Hepatology 38, 133-140 (2003).
147. 3 receptor antagonists with improved potency. J. Med. Chem. 48, 6482-6490 (2005).
148. Needleman, P. & Isakson, P. C. The discovery and function of COX-2. J. Rheumatol. 24 (Suppl. 49), 6-8 (1997).
149. Masferrer, J. L., Seibert, K., Zweifel, B. & Needleman, P. Endogenous glucocorticoids regulate an inducible cycloaxygenase enzyme. Proc. Natl Acad. Sci. USA 89, 3917-3921 (1992).
150. Menard, J. The 45-year story of the development of an anti-aldosterone more specific than spironolactone. Mol. Cell. Endocrinol. 217 45-52 (2004).
151. Sica, D. A. Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis. Heart Fail. Rev. 10, 23-29 (2005).
152. Manning, G., Whyte. D. B, Martinez. R., Hunter, T, & Sudarsanam, S. The protein Kinase complement of the human genome. Science 298, 1912-1934 (2002).
153. Ridings, J. E. & Baldwin, J. A. A qualitative assessment of developmental toxicity within a series of structurally related dopamine mimetics. Toxicology 76, 197-207 (1992).
154. Nomanbhoy, T. K., Rosenblum, J., Aban, A. & Burbaum, J. J. Inhibitor focusing: Direct selection of drug targets from proteomes using activity-based probes. Assay Drug Dev. Technol. 1, 137-146 (2003).
155. McKenney, J. M. Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: Benefits versus risks. Am. J. Cardiol. 96, 60E-66E-(2005).
156. Paoletti, R., Corsini, A. & Bellosta, S. Pharmacological interactions of statins. Atheroscler. Suppl. 3, 35-40 (2002).
157. Evans, M. & Rees, A. Effects of HMG-CoA reductase inhibitors on skeletal muscle: Are all statins the same? Drug Saf. 25, 649-663 (2002).
158. Ucar, M., Mjorndal, T. & Dahlqvist, R. HMG-CoA reductase inhibitors and myotoxicity. Drug Saf. 22, 441-457 (2000).
159. Zambrowicz, B. P. & Sands, A. T. Knockouts model the 100 best-selling drugs - will they model the next 100? Nature Rev. Drug Discov. 2, 38-51 (2003).
160. Hopkins. A. L. & Groom, C. R. The druggable genome. Nature Rev. Drug Discov. 1, 727-730 (2002).
161. Pennie, W., Pettit S. D. & Lord, P. G. Toxicogenomics in risk assessment: An overview of an HESI collaborative research program. Environ. Health Perspect. 112, 417-419 (2004).
162. Petruska, J. M. et al. Cardiovascular effects after inhalation of large doses of albuterol dry powder in rats, monkeys, and dogs: A species comparison. Fundam. Appl. Toxicol. 40, 52-62 (1997).
163. Broadhead, C. L. et al. Prospects for reducing and refining the use of dogs in the regulatory toxicity testing of pharmaceuticals. Hum. Exp. Toxicol. 19, 440-447 (2002).
164. Lipinski, C. A., Lombardo, F., Dominy, B. W. & Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46, 3-25 (1997).